Efficacy and safety of Aspirin use for primary prevention of cardiovascular disease in diabetic patients

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220804004

Enrollment

560

Registered

2022-08-04

Start date

2021-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic patient Aspirin Primary prevention Cardiovascular disease Diabetic patient Aspirin Primary prevention Cardiovascular disease

Interventions

Aspirin dose 75-162 mg/d oral OD is a medication used to reduce pain, fever, or inflammation and also used long-term to help prevent further heart attacks, ischaemic strokes, and blood clots in peopl

No Intervention Drug

Aspirin

Eligibility

Sex/Gender

All

Age

50 Years to 110 Years

Inclusion criteria

Inclusion criteria: Diabetic patient who diagnosis since 2010 at Pakchong Nana hospital

Exclusion criteria

Exclusion criteria: Diabetic patient who had Aspirin drug allergy and uncompleted all data to collect

Design outcomes

Primary

Measure	Time frame
Cardiovascular disease 10 years Retrospective data collection	—

Secondary

Measure	Time frame
Major gastrointestinal bleeding and Hemorrhagic stroke 10 years Retrospective data collection	—

Countries

Thailand

Contacts

Public ContactNicha Viratsasivimaol

Pakchong Nana Hospital

Nicha.virat@gmail.com0874470644

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026